1. Ovarian reserve in women with Type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
- Author
-
Valerie L. Arends, Catherine Kim, Aruna V. Sarma, Hunter Wessells, John F. Randolph, M. S. M. Lanham, Patricia A. Cleary, Barbara H. Braffett, Rodney L. Dunn, Melissa Wellons, and Michael W. Steffes
- Subjects
Adult ,Anti-Mullerian Hormone ,medicine.medical_specialty ,endocrine system ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Down-Regulation ,030209 endocrinology & metabolism ,Article ,law.invention ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Randomized controlled trial ,law ,Internal medicine ,Diabetes mellitus ,Epidemiology ,Internal Medicine ,medicine ,Humans ,Hypoglycemic Agents ,Insulin ,Longitudinal Studies ,Ovarian reserve ,Ovarian Reserve ,Glycemic ,Glycated Hemoglobin ,Type 1 diabetes ,030219 obstetrics & reproductive medicine ,business.industry ,medicine.disease ,Hypoglycemia ,Menopause ,Diabetes Mellitus, Type 1 ,Hyperglycemia ,Female ,business ,Biomarkers - Abstract
Markers of ovarian reserve such as anti-Mullerian hormone (AMH) are used in the management of fertility and prediction of menopause. Although women with type 1 diabetes have a high prevalence of reproductive disorders, no studies have examined whether markers of ovarian reserve are associated with randomization to intensive insulin therapy and subsequent markers of glycemic control. Using data from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study, we found that the strongest predictor of AMH was chronologic age, and that diabetes-specific variables such as randomization to intensive therapy, insulin dose, and glycemic control were not associated with AMH concentrations.
- Published
- 2016